Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-10-2013 | Original Article

Non-invasive imaging of glioma vessel size and densities in correlation with tumour cell proliferation by small animal PET and MRI

Authors: Thomas Viel, Philipp Boehm-Sturm, Sara Rapic, Parisa Monfared, Bernd Neumaier, Mathias Hoehn, Andreas H. Jacobs

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 10/2013

Abstract

Purpose

Angiogenesis is a key event in the progression of glioblastomas (GBM). Our goal was to measure different anatomical and physiological parameters of GBM vessels using steady-state contrast-enhanced magnetic resonance imaging (SSCE-MRI), together with the assessment of biochemical parameters on GBM proliferation and angiogenesis using [¹¹C]methyl-L-methionine (MET) and 3′-deoxy-3′-[¹⁸F]fluorothymidine (FLT) and positron emission tomography (PET). We focused on how these anatomical and biochemical read-outs correlate with one another and with immunohistochemistry.

Methods

SSCE-MRI together with ¹¹C-MET and ¹⁸F-FLT PET were performed 3 weeks after intracranial implantation of human GBM spheroids in nude rats (n = 8). Total cerebral blood volume (tCBV), blood volume present in microvessels (μCBV), vessel density and size were calculated. Rats were treated with bevacizumab (n = 4) or vehicle (n = 4) for 3 weeks. Imaging was repeated at week 6, and thereafter immunohistochemistry was performed.

Results

Three weeks after implantation, MRI showed an increase of vessel density and μCBV in the tumour compared to the contralateral brain. At week 6, non-treated rats showed a pronounced increase of ¹¹C-MET and ¹⁸F-FLT tumour uptake. Between weeks 3 and 6, tCBV and vessel size increased, whereas vessel density and μCBV decreased. In rats treated with bevacizumab μCBV values were significantly smaller at week 6 than in non-treated rats, whereas the mean vessel size was higher. Accumulation of both radiotracers was lower for the treated versus the non-treated group. Most importantly, non-invasive measurement of tumour vessel characteristics and tumour proliferation correlated to immunohistochemistry findings.

Conclusion

Our study demonstrates that SSCE-MRI enables non-invasive assessment of the anatomy and physiology of the vasculature of experimental gliomas. Combined SSCE-MRI and ¹¹C-MET/¹⁸F-FLT PET for monitoring biochemical markers of angiogenesis and proliferation in addition to vessel anatomy could be useful to improve our understanding of therapy response of gliomas.

Available only for authorised users

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225–49.PubMedCrossRef

Vredenburgh JJ, Desjardins A, Herndon 2nd JE, Dowell JM, Reardon DA, Quinn JA, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253–9.PubMedCrossRef

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733–40.PubMedCrossRef

Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841–4.PubMedCrossRef

Verhoeff JJ, van Tellingen O, Claes A, Stalpers LJ, van Linde ME, Richel DJ, et al. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 2009;9:444–53.PubMedCrossRef

Dhermain FG, Hau P, Lanfermann H, Jacobs AH, van den Bent MJ. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol 2010;9:906–20.PubMedCrossRef

Waerzeggers Y, Monfared P, Viel T, Winkeler A, Jacobs AH. Mouse models in neurological disorders: applications of non-invasive imaging. Biochim Biophys Acta 2010;1802:819–39.PubMedCrossRef

Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 2006;24:3293–8.PubMedCrossRef

Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223–32.PubMedCrossRef

10.

Koh TS, Zeman V, Darko J, Lee TY, Milosevic MF, Haider M, et al. The inclusion of capillary distribution in the adiabatic tissue homogeneity model of blood flow. Phys Med Biol 2001;46:1519–38.PubMedCrossRef

11.

Dennie J, Mandeville JB, Boxerman JL, Packard SD, Rosen BR, Weisskoff RM. NMR imaging of changes in vascular morphology due to tumour angiogenesis. Magn Reson Med 1998;40:793–9.PubMedCrossRef

12.

Jensen JH, Chandra R. MR imaging of microvasculature. Magn Reson Med 2000;44:224–30.PubMedCrossRef

13.

Wu EX, Tang H, Jensen JH. High-resolution MR imaging of mouse brain microvasculature using the relaxation rate shift index Q. NMR Biomed 2004;17:507–12.PubMedCrossRef

14.

Pannetier N, Lemasson B, Christen T, Tachrount M, Troprès I, Farion R, et al. Vessel size index measurements in a rat model of glioma: comparison of the dynamic (Gd) and steady-state (iron-oxide) susceptibility contrast MRI approaches. NMR Biomed 2012;25:218–26.PubMedCrossRef

15.

Ullrich RT, Jikeli JF, Diedenhofen M, Böhm-Sturm P, Unruh M, Vollmar S, et al. In-vivo visualization of tumour microvessel density and response to anti-angiogenic treatment by high resolution MRI in mice. PLoS One 2011;6:e19592.PubMedCrossRef

16.

Viel T, Talasila KM, Monfared P, Wang J, Jikeli JF, Waerzeggers Y, et al. Analysis of the growth dynamics of angiogenesis-dependent and -independent experimental glioblastomas by multi-modal small-animal PET and MRI. J Nucl Med 2012;53:1135–45.PubMedCrossRef

17.

Jacobs AH, Thomas A, Kracht LW, Li H, Dittmar C, Garlip G, et al. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 2005;46:1948–58.PubMed

18.

Machulla HJ, Blocher A, Kuntzsch M, Piert M, Wei R, Grierson JR. Simplified labeling approach for synthesizing 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT). J Radioanal Nucl Chem 2000;243:843–6.CrossRef

19.

Miller AJ, Joseph PM. The use of power images to perform quantitative analysis on low SNR MR images. Magn Reson Imaging 1993;11:1051–6.PubMedCrossRef

20.

Kiselev VG. Spin echo amplitude in biological tissue with implications for vessel size imaging. Joint Annual Meeting ISMRM-ESMRMB, Stockholm. 2010;01–07052010(1):1792.

21.

Hoehn-Berlage M, Eis M, Schmitz B. Regional and directional anisotropy of apparent diffusion coefficient in rat brain. NMR Biomed 1999;12:45–50.PubMedCrossRef

22.

Vollmar SCJ, Sue M, Klein J, Jacobs AH, Herholz K. VINCI - volume imaging in neurological research, co-registration and ROIs included. In: Kremer K, Macho V, editors. Research and Scientific Computing 2003. Göttingen: Gesellschaft für wissenschaftliche Datenverarbeitung; 2004. p. 115–31.

23.

Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nature Methods 2012;9:676–82.PubMedCrossRef

24.

Sakariassen PØ, Prestegarden L, Wang J, Skaftnesmo KO, Mahesparan R, Molthoff C, et al. Angiogenesis-independent tumour growth mediated by stem-like cancer cells. Proc Natl Acad Sci U S A 2006;103:16466–71.PubMedCrossRef

25.

Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A 2011;108:3749–54.PubMedCrossRef

26.

Beer AJ, Schwaiger M. Imaging of integrin alphavbeta3 expression. Cancer Metastasis Rev 2008;27:631–44.PubMedCrossRef

27.

Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci 2007;8:610–22.PubMedCrossRef

28.

Klein B, Kuschinsky W, Schröck H, Vetterlein F. Interdependency of local capillary density, blood flow, and metabolism in rat brains. Am J Physiol 1986;251:H1333–40.PubMed

29.

Schor AM, Pendleton N, Pazouki S, Smither RL, Morris J, Lessan K, et al. Assessment of vascularity in histological sections: effects of methodology and value as an index of angiogenesis in breast tumours. Histochem J 1998;30:849–56.PubMedCrossRef

30.

von Baumgarten L, Brucker D, Tirniceru A, Kienast Y, Grau S, Burgold S, et al. Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells. Clin Cancer Res 2011;17:6192–205.CrossRef

31.

Kiselev VG, Posse S. Analytical model of susceptibility-induced MR signal dephasing: effect of diffusion in a microvascular network. Magn Reson Med 1999;41:499–509.PubMedCrossRef

32.

Drevs J, Müller-Driver R, Wittig C, Fuxius S, Esser N, Hugenschmidt H, et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 2002;62:4015–22.PubMed

33.

Miletic H, Niclou SP, Johansson M, Bjerkvig R. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. Expert Opin Ther Targets 2009;13:455–68.PubMedCrossRef

34.

Okubo S, Zhen HN, Kawai N, Nishiyama Y, Haba R, Tamiya T. Correlation of L-methyl-11C-methionine (MET) uptake with L-type amino acid transporter 1 in human gliomas. J Neurooncol 2010;99:217–25.PubMedCrossRef

35.

Kracht LW, Friese M, Herholz K, Schroeder R, Bauer B, Jacobs A, et al. Methyl-[11C]-l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 2003;30:868–73.PubMedCrossRef

36.

Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F]fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007;25:4714–21.PubMedCrossRef

37.

Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Geist C, et al. 3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med 2012;53:29–36.PubMedCrossRef

Title: Non-invasive imaging of glioma vessel size and densities in correlation with tumour cell proliferation by small animal PET and MRI
Authors: Thomas Viel
Philipp Boehm-Sturm
Sara Rapic
Parisa Monfared
Bernd Neumaier
Mathias Hoehn
Andreas H. Jacobs
Publication date: 01-10-2013
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2013
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-013-2464-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Non-invasive imaging of glioma vessel size and densities in correlation with tumour cell proliferation by small animal PET and MRI

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2013

XVIIIth Congress of the György Hevesy Hungarian Society of Nuclear Medicine (MONT), Pécs, Hungary, 30 June – 2 July 2013

Elevated 18F-fluorodeoxyglucose uptake in the interventricular septum is associated with atrioventricular block in patients with suspected cardiac involvement sarcoidosis

The increment in standardized uptake value determined using dual-phase 18F-FDG PET is a promising prognostic factor in non-small-cell lung cancer

The Second Balkan Congress of Nuclear Medicine

[11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment

Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer